Arrail Group (“Arrail” or the “Company), a leading dental service provider in China, announced that it has closed its Series E financing, with a transaction value of nearly $200M. The transaction was led by Temasek, with participation from OrbiMed, Ward Ferry, Hina Group, Industrial Bank and Mirae Asset. CEC Capital Group was the exclusive financial advisor on this transaction, and is proud to have advised Arrail since its Series A round of financing.
PALO ALTO, CA, March 30, 2021 -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1/2 financing. The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Funds Management, and existing investors, including Northern Light Venture Capital and Vivo Capital. In addition, the company received a strategic capital investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP), directed toward advancing the company’s work to treat blood cancers. CEC Capital Group was the exclusive financial advisor on this transaction.